173 related articles for article (PubMed ID: 27683179)
21. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1.
Tian S; Hui X; Fan Z; Li Q; Zhang J; Yang X; Ma X; Huang B; Chen D; Chen H
FASEB J; 2014 Aug; 28(8):3528-39. PubMed ID: 24769671
[TBL] [Abstract][Full Text] [Related]
22. Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
Roh MR; Zheng Z; Kim HS; Jeung HC; Rha SY; Chung KY
Melanoma Res; 2013 Apr; 23(2):114-24. PubMed ID: 23358428
[TBL] [Abstract][Full Text] [Related]
23. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
24. Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate.
Ceaglio N; Etcheverrigaray M; Conradt HS; Grammel N; Kratje R; Oggero M
J Biotechnol; 2010 Mar; 146(1-2):74-83. PubMed ID: 20067809
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells.
Zhu S; Cao L; Yu Y; Yang L; Yang M; Liu K; Huang J; Kang R; Livesey KM; Tang D
Autophagy; 2013 Mar; 9(3):317-27. PubMed ID: 23242206
[TBL] [Abstract][Full Text] [Related]
26. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
27. Construction of recombinant human IFNα-2b BCG and its antitumor effects on bladder cancer cells in vitro.
Sun E; Nian X; Liu C; Fan X; Han R
Genet Mol Res; 2015 Apr; 14(2):3436-49. PubMed ID: 25966110
[TBL] [Abstract][Full Text] [Related]
28. Stat2 binding to the interferon-alpha receptor 2 subunit is not required for interferon-alpha signaling.
Nguyen VP; Saleh AZ; Arch AE; Yan H; Piazza F; Kim J; Krolewski JJ
J Biol Chem; 2002 Mar; 277(12):9713-21. PubMed ID: 11786546
[TBL] [Abstract][Full Text] [Related]
29. Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma.
Wang CJ; Xiao CW; You TG; Zheng YX; Gao W; Zhou ZQ; Chen J; Xue XB; Fan J; Zhang H
Mol Cancer; 2012 May; 11():31. PubMed ID: 22569271
[TBL] [Abstract][Full Text] [Related]
30. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2.
Dhalluin C; Ross A; Huber W; Gerber P; Brugger D; Gsell B; Senn H
Bioconjug Chem; 2005; 16(3):518-27. PubMed ID: 15898717
[TBL] [Abstract][Full Text] [Related]
31. Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo.
Bingfa X; Qinglin F; Hui H; Canjun W; Wei W; Lihua S
Pharmacology; 2009; 83(6):323-32. PubMed ID: 19407486
[TBL] [Abstract][Full Text] [Related]
32. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
Tenesaca S; Vasquez M; Alvarez M; Otano I; Fernandez-Sendin M; Di Trani CA; Ardaiz N; Gomar C; Bella A; Aranda F; Medina-Echeverz J; Melero I; Berraondo P
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321273
[TBL] [Abstract][Full Text] [Related]
33. The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action.
Pfeffer LM; Basu L; Pfeffer SR; Yang CH; Murti A; Russell-Harde D; Croze E
J Biol Chem; 1997 Apr; 272(17):11002-5. PubMed ID: 9110990
[TBL] [Abstract][Full Text] [Related]
34. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the responses of different recombinant fish type I interferons against betanodavirus infection in grouper.
Kuo HP; Chung CL; Hung YF; Lai YS; Chiou PP; Lu MW; Kong ZL
Fish Shellfish Immunol; 2016 Feb; 49():143-53. PubMed ID: 26691305
[TBL] [Abstract][Full Text] [Related]
36. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.
Marijanovic Z; Ragimbeau J; van der Heyden J; Uzé G; Pellegrini S
Biochem J; 2007 Oct; 407(1):141-51. PubMed ID: 17627610
[TBL] [Abstract][Full Text] [Related]
37. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
38. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities.
Huang TH; Chintalacharuvu KR; Morrison SL
J Immunol; 2007 Nov; 179(10):6881-8. PubMed ID: 17982079
[TBL] [Abstract][Full Text] [Related]
39. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
40. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells.
Gazziola C; Cordani N; Carta S; De Lorenzo E; Colombatti A; Perris R
Int J Oncol; 2005 Jan; 26(1):129-40. PubMed ID: 15586233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
